Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LR-ESHAP · 1 trial · 1 indication
To determine the MTD of the combination R-ESHAP with lenalidomide
To determine the overall response rate of LR-ESHAP
| Arm | Type | Description |
|---|---|---|
| LR-ESHAP (lenalidomide 5 mg) | EXPERIMENTAL | Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)). |
| LR-ESHAP (lenalidomide 10mg) | EXPERIMENTAL | Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)). |
| LR-ESHAP (lenalidomide 15mg) | EXPERIMENTAL | Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)). |
| LR-ESHAP (lenalidomide 20mg) | EXPERIMENTAL | Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)). |
| Name | Type | Description |
|---|---|---|
| LR-ESHAP (lenalidomide 5 mg) | DRUG | 3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks. |
| LR-ESHAP (lenalidomide 10 mg) | DRUG | 3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks. |
| LR-ESHAP (lenalidomide 15 mg) | DRUG | 3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks. |
| LR-ESHAP (lenalidomide 20 mg) | DRUG | 3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks. |
Inclusion Criteria: 1. The patient must, at the investigator's opinion, be able to meet all requirements of the clinical trial. 2. Patients must give voluntarily informed consent before performing any test test that is not part of routine care of patients. 3. Age between 18 and 70 years. 4. Candida...
LR-ESHAP is an investigational small molecule being studied for the treatment of Diffuse Large B-cell Lymphoma (DLBCL). It is a combination regimen that includes lenalidomide and rituximab, along with the ESHAP chemotherapy components. The drug is currently in clinical development and has not been approved by regulatory authorities.
LR-ESHAP is being developed by Thermo Fisher Scientific Inc, a company publicly traded under the ticker symbol TMO. The company is conducting clinical research to evaluate the safety and efficacy of this drug combination in patients with Diffuse Large B-cell Lymphoma.
LR-ESHAP is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. A Phase 1 clinical trial has been completed to determine the dose, safety, and efficacy of the lenalidomide and rituximab (LR)-ESHAP combination in patients with Diffuse Large B-cell Lymphoma.
LR-ESHAP has one completed clinical trial registered under NCT02340936. This Phase 1 study, titled "Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma," enrolled 53 participants in Spain. The trial included adults aged 18 years and older.
LR-ESHAP is a combination regimen that includes lenalidomide and rituximab, but it is not the same as those drugs alone. The name LR-ESHAP refers to the full combination of lenalidomide (L), rituximab (R), and the ESHAP chemotherapy regimen. It is being studied specifically for Diffuse Large B-cell Lymphoma.